Long-term follow-up confirms sustained efficacy of pembrolizumab in heavily pretreated PMBCLMay 18, 2023B Cell Lymphoma
Survival outcomes after early termination of R-CHOP in diffuse large B-cell lymphomaMay 18, 2023B Cell Lymphoma
Orelabrutinib offers a promising treatment option for relapsed or refractory MCLMay 18, 2023B Cell Lymphoma
First-line autologous stem cell transplantation provides sustained remission in disseminated MCLMay 18, 2023B Cell Lymphoma
Specific SNP may predict lenalidomide efficacy after autologous stem cell transplantation in MCLMay 18, 2023B Cell Lymphoma
Venetoclax achieves a high undetectable measurable residual disease rate in ibrutinib-treated high-risk CLLMay 18, 2023B Cell Lymphoma
Chemotherapy+rituximab causes prolonged hypogammaglobulinemia in children with mature B-NHLMay 18, 2023B Cell Lymphoma
Short subcutaneous rituximab maintenance after induction improves outcomes in low-tumor burden FLMay 18, 2023B Cell Lymphoma
First-line venetoclax-obinutuzumab +/− ibrutinib tops chemoimmunotherapy in advanced CLLMay 18, 2023B Cell Lymphoma
